The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1263 articles
Hims & Hers investment narrative shifts amid legal scrutiny on compounded GLP-1 agonists. A January 2026 antitrust lawsuit accuses Eli Lilly and Novo Nordisk of blocking compounded Mounjaro and Wegovy. This raises uncertainties for telehealth providers reliant on these affordable weight management options.
GLP-1 medications are revolutionizing not just weight loss but how people approach food, prioritizing protein quality over quantity. Research shows users eat less overall, including less meat, yet value nutrient-dense proteins more highly. These changes signal premiumization in the food sector and broader economic impacts. (~198 chars)
A registered nurse in Chicago is under federal charges for handing out counterfeit versions of the weight-loss medication Ozempic. The drugs, which did not contain the key component semaglutide, were allegedly distributed to three people. She has pleaded not guilty and faces potential jail time.
An analysis of public data shows that pharmaceutical firms paid over $533,000 to Indiana healthcare professionals in 2024 for speaking about GLP-1 medications. The funds covered travel and expenses for conferences. Experts discuss potential influences on prescribing practices, while doctors defend the educational value.
The Food and Drug Administration announced on Tuesday its desire to remove suicide warning labels from GLP-1 weight-loss medications. A comprehensive review of 91 trials revealed no heightened risk of suicidal thoughts or behaviors among users compared to placebo groups. This change aligns the labels with those of diabetes equivalents from the same manufacturers.
The new Wegovy GLP-1 pill for weight loss is now accessible in New Jersey stores. With growing interest in these medications, this guide covers availability, pricing, and key safety information. Health tracking apps like Shotlee can assist in monitoring progress during use.
Wall Street experts highlight unexpected benefits for airlines from GLP-1 medications like Ozempic, including significant fuel cost reductions due to lighter travelers. Analysts predict that widespread adoption could lead to billions in savings by reducing aircraft weight. This trend intersects pharmaceutical advancements with aviation economics.
According to a Calgary doctor, affordable generic alternatives to drugs like Ozempic and Wegovy might reduce expenses by up to a third. The content explores regional approaches to obesity management in Canada, emphasizing the challenges of rewiring brain circuitry and the role of medications in promoting healthier eating habits.
Controversial podcaster Tucker Carlson has sparked online worries with his noticeably altered appearance in a recent photo, fueling speculation about using GLP-1 medications like Ozempic. This comes as weight-loss drugs gain mainstream traction, highlighted by Donald Trump's openness to them and recent policy changes. Social media users have reacted strongly, questioning his health amid his health advocacy role.
